Whether your neuropathy gets worse depends far more on whether the driver damaging your nerves is still active than on the word “neuropathy” itself. That is the whole answer, and it is also why nobody can give you a timeline until the driver has been identified.
Peripheral neuropathy is the most common reason for an outpatient neurology visit in the United States and accounts for over $10 billion in health care spending each year.1 A great deal of that reflects how long people live with a diagnosis that names the symptom rather than the cause. Progression is not one fixed path, and it is measurable.
What progression usually looks like
People usually mean symptoms when they say progression, but symptoms are only one of the things that change. Sensation, balance, strength and daily function can all shift, sometimes in different directions at once.
Length-dependent and symmetrical patterns
In many metabolic forms, the longest nerve fibers fail first. That is why symptoms typically start in the toes and move upward, and why the hands are often affected later, once the pattern has reached roughly mid-calf.
The pattern is also usually symmetrical. Symmetry points toward a systemic driver; a one-sided or patchy pattern points somewhere else entirely, which is a useful thing for your clinician to notice early.
Small fiber involvement can progress when standard testing looks normal
Burning, hot-coal sensations and altered pain and temperature perception can be present while a routine nerve conduction study looks unremarkable, because that study measures large fibers.
A normal result in that setting is not reassurance that nothing is progressing. It is a signal that the workup needs to match the symptom pattern rather than stop.
Drivers that keep progression active
Peripheral neuropathy is a category, not a diagnosis. These are the driver groups worth working through, and more than one can be present in the same person.
Metabolic injury
When glucose runs high, sugars bind to proteins in a slow browning reaction that produces advanced glycation end-products, and those accumulate in the nerve environment. Impaired flow through the small vessels that feed the nerve compounds it, because the longest fibers depend on the most fragile part of that supply.
The practical point is that while the metabolic driver runs, injury continues, whether or not symptoms happen to be quiet that week. Symptom intensity and disease activity are two different things.
Nutritional drivers
B12 deficiency can produce progressive nerve dysfunction, and it keeps producing it until the deficiency is corrected. Diet, absorption after gastrointestinal surgery, and medications that interfere with absorption all belong in the history.
Autoimmune and immune-reactive patterns
Immune-mediated processes, including gluten-related nerve injury, can drive symptoms that keep advancing while the immune activity continues. These patterns are frequently the ones sitting behind an idiopathic label.
Toxic and medication-related exposures
Chemotherapy-related nerve injury follows the exposure timeline, so the history and the symptom course have to be read together. Heavy metals such as lead, arsenic and mercury are the other exposure group worth ruling in or out when the history suggests it.
Structural compression
Not everything that looks like neuropathy is systemic. When symptoms follow the territory of a single nerve, progression may be driven by compression and local inflammation instead, which responds to entirely different treatment. The distinction is covered in nerve compression: carpal tunnel, sciatica and double-crush patterns.
Why testing changes the answer
Progression is change over time, and change over time is only meaningful against a baseline. Without one, every visit is a fresh guess about whether things are moving.
Electrodiagnostic testing (EMG/NCS) is performed on site here and characterizes large-fiber conduction. Where unsteadiness, dizziness or falls are part of the picture, VNG is used as a diagnostic test of inner-ear balance function — it is not a treatment, and it does not measure peripheral nerves.
Metabolic and nutritional assessment runs alongside both, because that is where most of the modifiable drivers actually live.
What can and cannot be promised
We do not promise that nerve damage can be regenerated or reversed. What a driver-directed plan aims at is different and more defensible: identifying what is still causing injury, reducing it where it can be reduced, and protecting function.
Symptom treatment has a place inside that. Qutenza (capsaicin 8% patch) is FDA-approved in adults only for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet; use for any other driver is off-label and is described as such. It is applied in clinic by a clinician and repeated no more often than every three months.
Orthobiologic injections such as PRP and BMAC are offered in selected situations. Better sleep and less pain are worth having in their own right, but neither changes the driver.
When to be evaluated sooner rather than later
Some changes are worth acting on quickly rather than watching.
- Numbness that is spreading upward, or newly involving the hands.
- Pain that has begun disrupting sleep, or pain triggered by light touch such as a bedsheet.
- New unsteadiness, dizziness, or any fall.
- Difficulty with stairs, weakness, or a foot that catches when you walk.
- Any break in the skin, blister or hot, swollen foot when sensation is reduced.
- A high-risk history: diabetes, chemotherapy, known B12 risk, or a significant exposure.
When protective sensation is reduced, daily foot inspection stops being optional. A numb foot no longer reports injury, so the eyes have to do the job the nerves used to do.
Start with the Nerve Damage Score
The Nerve Damage Score is five questions, and it is free. It is built to point at which driver is most likely responsible in your case, which is the only honest starting point for a conversation about whether things will get worse.
Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134. Call or text (314) 886-5902, or email info@regenerve.com. We are minutes from St. Louis Lambert International Airport and see patients from across the St. Louis region, Missouri and Illinois, including Edwardsville, Glen Carbon, Collinsville, Troy and Maryville.
Frequently asked questions
My feet burn at night. Does that mean it is getting worse?
Not by itself. Night-time burning is common early and does not reliably track severity, so intensity on a given night is a poor progression measure. What matters is whether sensation, balance and function are changing over months. See small fiber neuropathy symptoms and testing.
How do clinicians predict whether neuropathy will progress?
By identifying the driver and then watching whether it is still active. A driver that is being corrected and a driver that is untouched produce very different trajectories in the same person. See the hidden drivers of peripheral neuropathy.
My blood sugar is under control now. Am I safe?
Better glucose handling reduces one source of ongoing injury, but it is not the whole terrain. Lipids, blood pressure, microvascular health, nutritional status and any additional driver all continue to matter. See diabetic peripheral neuropathy treatment in St. Louis.
What if nobody has found a cause for my neuropathy?
Idiopathic is a status, not a verdict. It usually means the workup stopped before the less common drivers were examined, including deficiency states, immune-reactive patterns and exposures. See functional B12 deficiency and neuropathy.
Could an exposure be making mine worse without my knowing?
It is possible, and it is worth ruling in or out rather than assuming. Heavy metals such as lead, arsenic and mercury are the classic example, and exposure history is often the only clue before testing. See heavy metals and neuropathy.
Sources
- Tavee JO. Office approach to small fiber neuropathy. Cleveland Clinic Journal of Medicine. 2018;85(10):801–812. ccjm.org